Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine

Ashwin C Parenky1, Archana Akalkotkar2, Nihal S Mulla3

  • 1Mercer University, Vaccine Nanotechnology Laboratory, Center for Drug Delivery Research, Atlanta, GA 30341, USA.

Vaccine
|September 4, 2019
PubMed

Insights

An oral microparticulate vaccine targeting prostate cancer antigens, when combined with cyclophosphamide and GM-CSF, significantly reduced tumor volume in mice. This combination therapy also boosted anti-tumor T-cells and decreased immune-suppressing T-regulatory cells.

Area of Science:

  • Immunology
  • Oncology
  • Materials Science

Background:

  • Prostate cancer immunotherapy requires strategies to enhance tumor regression and prevent recurrence.
  • Tumor-associated antigens (TAA) are key targets for cancer vaccines.
  • Immune stimulating adjuvants can potentiate vaccine efficacy.

Purpose of the Study:

  • To formulate and characterize an oral microparticulate vaccine encapsulating prostate cancer TAA.
  • To evaluate the in vitro immune-stimulating potential of the microparticle vaccine.
  • To assess the in vivo anti-tumor efficacy of the vaccine in combination therapy.

Main Methods:

  • Spray-dried microparticles encapsulating TRAMP-C2 derived TAA were formulated.
  • In vitro characterization included size, zeta potential, and immune cell marker analysis (CD80/86, CD40, MHC-I/II) on dendritic cells.
  • In vivo studies involved administering the vaccine with cyclophosphamide and GM-CSF to C57BL/6 mice and measuring tumor volume and T-cell populations.

Main Results:

  • Microparticles exhibited optimal physicochemical properties (4.92 μm size, 7.92 mV zeta potential) and induced dendritic cell activation.
  • Combination therapy with cyclophosphamide and GM-CSF resulted in a five-fold reduction in tumor volume compared to controls.
  • Significant increases in cytotoxic T-cells (CD8+) and T-helper cells (CD4+), alongside a decrease in T-regulatory cells, were observed.

Conclusions:

  • Oral microparticulate vaccines effectively deliver prostate cancer antigens and stimulate an anti-tumor immune response.
  • Combination therapy with cyclophosphamide and GM-CSF enhances vaccine efficacy, reducing tumor growth and modulating the tumor microenvironment.
  • This approach shows promise for overcoming immune evasion mechanisms in prostate cancer.

Related Concept Videos

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult...
14.6K
Intra-prostatic Injection of Cancer Cells: A Technique to Deliver Cancer Cells for Establishing Orthotopic Prostate Cancer Mouse Model05:07

Intra-prostatic Injection of Cancer Cells: A Technique to Deliver Cancer Cells for Establishing Orthotopic Prostate Cancer Mouse Model

In this video, we demonstrate the procedure for administering intra-prostatic injection of prostate cancer cells into a mouse model. Orthotopic murine models can be used to study the disease origin and response to treatment therapies in a non-invasive and clinically relevant...
5.7K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

This orthotopic model of human prostate cancer allows for quantification of tumor size, circulating tumor cells, and formation of distinct metastasis to the lung. As cells must escape the primary organ, enter the blood stream, and implant into a secondary site, this model effectively recapitulates the scenario in...
35.8K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Overtreatment is often administered to patients with low-risk prostate cancer; super-active surveillance can help avoid such...
687
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells08:03

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

This manuscript details a method used to generate prostate cancer patient derived xenografts (PDXs) from circulating tumor cells (CTCs). The generation of PDX models from CTCs provides an alternative experimental model to study prostate cancer; the most commonly diagnosed tumor and a frequent cause of death from cancer in...
14.6K
Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer08:54

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer

We show a method for necropsy and dissection of mouse prostate cancer models, focusing on prostate tumor dissection. A step-by-step protocol for generation of mouse prostate tumor organoids is also...
11.3K